Pharmaceutical Research

, Volume 29, Issue 1, pp 35–52

Cellular Reprogramming: A New Technology Frontier in Pharmaceutical Research

Expert Review

DOI: 10.1007/s11095-011-0618-z

Cite this article as:
Brock, A., Goh, H., Yang, B. et al. Pharm Res (2012) 29: 35. doi:10.1007/s11095-011-0618-z

Abstract

Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

Key Words

cellular reprogrammingdrug discoveryiPSCpharmaceutical researchstem cells

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Wyss Institute for Biologically Inspired EngineeringHarvard UniversityBostonUSA
  2. 2.Epigenetics & Cell Fates LaboratoryA*STAR Institute of Medical BiologySingaporeSingapore
  3. 3.Department of Biological Chemistry & Molecular PharmacologyHarvard Medical SchoolBostonUSA
  4. 4.Department of Biomedical Engineering & Center for BioDynamicsBoston UniversityBostonUSA
  5. 5.Department of Biological SciencesNational University of SingaporeSingaporeSingapore
  6. 6.Wyss Institute, Harvard Medical SchoolBostonUSA